AZN241129P100000
- 0.00
- 0.000.00%
AstraZeneca Newsroom
Novo Nordisk and AstraZeneca Top of the 2025 Drug Picks for US Investment Bank - Read Why | NYSE:NVO
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca Hits 4-week High
Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.
Sanofi will invest about 1 billion euros (about 1.1 billion dollars) to build a new insulin production base in peking. This is its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production base in china and its second in peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential of the diabetes treatment market in china is enormous. According to Sanofi, as of 2021, approximately 0.14 billion adults in mainland china have diabetes.
Sanofi Unveils $1 Billion China Investment to Boost Production
AstraZeneca PLC ADR Falls Monday, Underperforms Market
AstraZeneca Announces Share Capital and Voting Rights
Why AstraZeneca PLC (AZN) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
Top Stock Reports for Chevron, AstraZeneca & Arista Networks
Trump 'sells off' European pharmaceutical stocks, can only rely on 'Americanization' to stop the decline?
The growth prescription for European pharmaceutical companies: shifting towards the usa.
Astrazeneca (AZN.US) Class 1 new drug approved for clinical trials in China for the first time, aiming to develop treatment for heart failure.
Astrazeneca (AZN.US) has received an implied license for clinical trials of its Class 1 new drug AZD5462 in china, which is intended for the treatment of heart failure.
Express News | The latest study in The Lancet: a historic breakthrough in the treatment of asthma and COPD.
AstraZeneca Partner's Orpathys Secures Renewal on China's Drug Reimbursement List
Express News | Astrazeneca appoints new position in oncology business, with Chinese background, expected to become a "bridge" to China.
AstraZeneca's Breast Cancer Drug Wins State Insurance Coverage in China
Express News | Astrazeneca's "breast cancer ADC miracle drug" DS-8201 has been added to the new version of the medical insurance catalog.
AstraZeneca's Strategic Focus and Clinical Trial Success Bolster Buy Rating
Failure of AstraZeneca's AZD4041 a Blow for Non-opioid OUD Treatments
Amgen (AMGN.US) releases mid-term data for weight loss therapy MariTide, with weight loss results comparable to Novartis.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide has achieved significant results in Phase 2 trials.